IASIS PHARMA is pleased to announce the RosuZet® launching, in the formulation of film-coated tablets.

RosuZet® is the fixed dose combination of Rosuvastatin – Ezetimibe, two active ingredients that reduce serum lipid levels with complementary mechanisms of action. Pharmacotherapeutic Class: Lipid Modifying Agents, HMG CoA reductase inhibitors in combination with other lipid modifying agents.

RosuZet® is indicated as an adjunct therapy to the diet for the treatment of primary hypercholesterolemia for adult patients adequately controlled with the drugs administered individually at the same dose level.

RosuZet®, as a fixed dose combination is indicated to reduce the risk of cardiovascular events as therapy for patients with coronary heart disease (CHD) and history of acute coronary syndrome (ACS), who are adequately controlled with individual agents administerted individually at the same dose.

It is available in packs of 30 film-coated tablets and in a wide dosage range:

  • RosuZet® F.C.TAB (5+10)mg
  • RosuZet® F.C.TAB (10+10)mg
  • RosuZet® F.C.TAB (20+10)mg
  • RosuZet® F.C.TAB (40+10)mg